Xing Ji

Xing Ji

Auto-generated profile, based on publicly available information

Xing Ji

Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2021 in World Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
YZYuanyuan Zeng
Yuanyuan Zeng
FCFeng Chen
Feng Chen
YZYong Zhang
Yong Zhang
XJXing Ji
Xing Ji

1 January 2023 in Current Drug Metabolism
Verified
Journal Article
Closed access
PDF file
YLYao Liu
Yao Liu
XGXu-Hua Ge
Xu-Hua Ge
HGHong-Li Guo
Hong-Li Guo
FCFeng Chen
Feng Chen
YZYong Zhang
Yong Zhang
HMHongjun Miao
Hongjun Miao
Background: Selection of the optimal antimicrobial posology in critically ill patients remains a challenge, especially in patients with sepsis who undergo continuous renal replacement therapy (CRRT). This systematic review aimed to analyze factors that influence the extracorporeal removal of linezolid. Methods: A comprehensive search was performed to identify studies published up to March 2022 in PubMed, MEDLINE and EMBASE databases. Studies involving adults receiving CRRT and treatment with linezolid were considered eligible if the CRRT setting and linezolid’s pharmacokinetic parameters were clearly mentioned. Results: Six out of 110 potentially relevant studies were included. A total of 101 treatments were identified among 97 enrolled patients. Our analysis showed that continuous veno-venous hemodiafiltration (CVVHDF) was the most frequential used modality (52 cases). Despite distribution volume, the clearance (CL) of linezolid in these studies had large variability. Extracorporeal linezolid removal may be markedly impacted by CRRT dose. There is significant between-subject variability in the probability of pharmacokinetics-pharmacodynamics (PK-PD) target attainment of patients treated with CRRT. Conclusion: Dose adjustment, shortening the dosing interval, and continuous infusion were proposed as regimen optimization. Therapeutic drug monitoring is recommended due to the high variability of linezolid exposure among patients with CRRT, specifically for those whose bodyweight is high, renal function is preserved, and the MIC of infection bacteria is above 2 μg/mL.

11 August 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
CPChengyu Pan
Chengyu Pan
MLMengru Liu
Mengru Liu
HLHui Li
Hui Li
LWLanfu Wei
Lanfu Wei
PWPengcheng Wang
Pengcheng Wang
YTYaozhou Tian
Yaozhou Tian
Objective. To systematically evaluate the efficacy and safety of Huangqin Tang (HQT) combined with mesalazine for the treatment of ulcerative colitis (UC). Methods. The China Knowledge Network, Wanfang Data, VIP, PubMed, SinoMed, Embase, and Cochrane Library databases were searched for randomized controlled trials (RCTs) of UC with HQT in Chinese and English. The search time was from the establishment of the database to October 2021. The included literature was evaluated for data extraction and risk of bias, efficacy and safety were evaluated using the RevMan5.3 software, and the quality of evidence was evaluated using GRADE. Results. Six studies with a total of 565 subjects were included, and a meta-analysis showed that HQT combined with mesalazine for UC significantly improved the cure rate (RR = 1.56, 95% CI [1.23, 1.98), ) and overall efficacy rate (RR = 1.24, 95% CI [1.14, 1.35], ), which significantly reduced the clinical symptom scores; however, all had high heterogeneity. HQT combined with mesalazine modulated the patients’ serum IL-6, IL-10, IgA, and IgG levels. HQT combined with mesalazine for UC tended to reduce adverse effects; however, the difference was not statistically significant. All GRADE ratings of the quality of evidence were of low quality. Conclusions. HQT combined with mesalazine in the treatment of UC significantly improved the cure rate and overall treatment efficiency and regulated the expression levels of serum IL-6, IL-10, IgA, and IgG.